Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures

Area of Science:

• Dermatology
• Clinical Trials
• Health Outcomes

Background:

• Biologic therapies like ixekizumab can achieve high Psoriasis Area and Severity Index (PASI90) response rates in moderate-to-severe psoriasis.
• Current Merit-based Incentive Payment System (MIPS) criteria may represent a lower threshold for treatment response.
• This could potentially lead to under-treatment and suboptimal quality of life (QoL) for psoriasis patients.

Purpose of the Study:

• To compare the Psoriasis Area and Severity Index (PASI90) response criteria against Merit-based Incentive Payment System (MIPS) criteria.
• To evaluate the association between PASI90 and MIPS response and patient-reported outcomes (PROs), including quality of life (QoL).
• To demonstrate that PASI90 represents a more rigorous standard of care.

Main Methods:

• A pooled analysis of three phase 3 clinical trials (UNCOVER-2/3, IXORA-S) involving ixekizumab for moderate-to-severe psoriasis.
• Patients were categorized based on achieving PASI90 or meeting MIPS criteria (static Physician Global Assessment ≤2, body surface area <3%, PASI <3, or Dermatology Life Quality Index ≤5).
• Improvements in QoL and other PROs were compared between PASI90 responders and MIPS-only responders.

Main Results:

• All patients achieving PASI90 also met MIPS criteria.
• A subset of MIPS responders did not achieve PASI90 (MIPS-only responders).
• PASI90 responders demonstrated significantly greater improvements across multiple health and QoL outcome measures compared to MIPS-only responders.

Conclusions:

• PASI90 is a more stringent measure of treatment response in psoriasis than MIPS criteria.
• Achieving PASI90 is associated with superior improvements in patient health and quality of life.
• This highlights the importance of utilizing higher response benchmarks for optimal psoriasis management.